Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transpl. 2006;6(5 Pt 1):859–66. https://doi.org/10.1111/j.1600-6143.2006.01288.x.

Article  CAS  Google Scholar 

Du J, Wang H, Zhong CB, Zhang M, Li B, Huo S, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282(20):15073–80. https://doi.org/10.1074/jbc.M701654200.

Article  CAS  PubMed  Google Scholar 

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. A systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. https://doi.org/10.3389/fimmu.2019.01990. eCollection 2019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous Immunoglobulin action in the treatment of autoimmune disorders. BioDrugs. 2002;16(1):47–55. https://doi.org/10.2165/00063030-200216010-00005.

Article  CAS  PubMed  Google Scholar 

Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous Immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10(3):165–9. https://doi.org/10.1016/s1246-7820(03)00035-1.

Article  CAS  PubMed  Google Scholar 

MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert KE, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune Globulin. Transfusion. 2018;58(11):2729–35. https://doi.org/10.1111/trf.14841.

Article  CAS  PubMed  Google Scholar 

Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous Immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158(Suppl 1):23–33. https://doi.org/10.1111/j.1365-2249.2009.04024.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449–56. PMID: 26053285.

PubMed  Google Scholar 

Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune Globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–51. https://doi.org/10.1056/NEJMoa0707894.

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1186/s13643-020-01542-z.

Article  PubMed  PubMed Central  Google Scholar 

Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous Immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861–9. https://doi.org/10.1016/j.ophtha.2009.09.049.

Article  PubMed  Google Scholar 

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR, Ahmed AR, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune Globulin. N Engl J Med. 2006;355(17):1772–9. https://doi.org/10.1056/NEJMoa062930.

Article  CAS  PubMed  Google Scholar 

Mühlhoff C, Megahed M. Behandlung eines therapieresistenten pemphigus vulgaris Mit rituximab und Immunglobulinen. Hautarzt. 2007;58:924–6. https://doi.org/10.1007/s00105-007-1414-x.

Article  PubMed  Google Scholar 

Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. J Dermatol. 2012;166(3):511–7. https://doi.org/10.1111/j.1365-2133.2011.10658.x.

Article  CAS  Google Scholar 

Namba C, Tohyama M, Hanakawa Y, Murakami M, Shirakata Y, Matsumoto T, Suemori K, Ishii N, Hashimoto T, Sayama K, Namba C, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: treatment with cyclosporin in addition to steroid, rituximab and intravenous Immunoglobulin. J Dermatol. 2016;43(4):419–22. https://doi.org/10.1111/1346-8138.13160.

Article  CAS  PubMed  Google Scholar 

Hamadah I, Chisti MA, Haider M, Binamer Y, Alajlan S, Aleyouni Y, Alfadley A. Rituximab/IVIG in pemphigus - a 10-year study with a long follow-up. J Dermatolog Treat. 2019;30(2):170–5. https://doi.org/10.1080/09546634.2018.1484873.

Article  CAS  PubMed  Google Scholar 

Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74(4):700–e83. https://doi.org/10.1016/j.jaad.2015.11.030.

Article  PubMed  Google Scholar 

Steger B, Madhusudan S, Kaye SB, Stylianides A, Romano V, Maqsood SE, Harper J, Ahmad S. Combined use of rituximab and intravenous Immunoglobulin for severe autoimmune cicatricial conjunctivitis. An interventional case series. Cornea. 2016;35(12):1611–4. https://doi.org/10.1097/ICO.0000000000001024.

Article  PubMed  Google Scholar 

Foschi CM, Maloney C, Amber KT. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022;20(4):520–1. https://doi.org/10.1111/ddg.14720.

Article  PubMed  Google Scholar 

Narayanan A, Pangti R, Agarwal S, Bhari N. Pemphigoid gestationis: a rare pregnancy dermatosis treated with a combination of IVIg and rituximab. BMJ Case Rep. 2021; 14(3): e24149 6. https://doi.org/10.1136/bcr-2020-241496

Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous Immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012;95(1):102–6. https://doi.org/10.1007/s12185-011-0968-7.

Article  CAS  PubMed  Google Scholar 

Andrés C, Teijeiro R, Saiz A, Fernandez P, Sánchez-Ramón S. [Cambios En Las subpoblaciones de linfocitos B y T En El Título de anticuerpos anti-acuaporina-4 Tras El Tratamiento de Un brote Agudo Con inmunoglobulinas y rituximab]. Neurologia. 2015;30(5):276–82. https://doi.org/10.1016/j.nrl.2013.12.022.

Article  PubMed  Google Scholar 

Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35(1):66–9. https://doi.org/10.1002/mus.20664.

Article  CAS  PubMed  Google Scholar 

Gertner E, Rosenbloom MH. Susac syndrome with prominent dermatological findings and a prompt response to intravenous Immunoglobulin, steroids, and rituximab: a case report. J Med Case Rep. 2016;10(1):137. https://doi.org/10.1186/s13256-016-0917-4.

Article  PubMed  PubMed Central  Google Scholar 

Watson E, Minehan S, White R. It’s never Lupus … until it is; Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis treated with intravenous immunoglobulin and rituximab: a case study. Neurology. 2017;88 (S-16):6–191. 10.1212/WNL.88.16_supplement.P6.191.

Oktem A, Akay BN, Boyvat A, Kundakci N, Erdem C, Bostancı S, et al. Long-term results of rituximab-intravenous Immunoglobulin combination therapy in patients with epidermolysis Bullosa acquisita resistant to conventional therapy. J Dermatolog Treat. 2017;28(1):50–4. https://doi.org/10.1080/09546634.2016.117971.

Article  CAS  PubMed  Google Scholar 

Birnbaum J, Lalji A, Piccione EA, Izbudak I. Magnetic resonance imaging of the spinal cord in the evaluation of 3 patients with sensory neuronopathies: diagnostic assessment, indications of treatment response, and impact of autoimmunity: A case report. Med (Baltim). 2017;96(49):e8483. https://doi.org/10.1097/MD.0000000000008483.

Article  Google Scholar 

Lima K, Tavee J, Dua A. Combination rituximab and intravenous Immunoglobulin for treatment of refractory vasculitic neuropathy: a case series. Rheumatology (Oxford). 2021;60(10):4884–7. https://doi.org/10.1093/rheumatology/keab069.

Article  PubMed  Google Scholar 

Cid J, Pérez-Valencia AI, Torrente MÁ, Ávarez-Larrán A, Díaz-Ricart M, Esteve J, et al. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous Immunoglobulins (CASPERI). Transfus Apher Sci. 2021;60(1):103011. https://doi.org/10.1016/j.transci.2020.103011.

Article  PubMed  Google Scholar 

Cheikh MM, Bahakim AK, Aljabri MK, Alharthi SM, Alharthi SM, Alsaeedi AK, et al. Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and Rituximab: An alternative to standard of care. Case Rep Rheumatol. 2022; 2022:5899188. https://doi.org/10.1155/2022/5899188

Castillo DR, Sheth P, Nishino K, Stevens WT, Nguyen A, Romagnolo A, et al. Successful treatment of autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus in a post-heart transplant patient. Hematol Rep. 2022;14(3):261–4.